RxDoctor Payments Data

Kyle Buchanan, MD

Interventional Cardiology · Bethel Park, PANPI 1447577655

Payments from drug & device makers

$9,203in general payments, 2019–2025

Across 226 payments — averaging $40.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • W. L. Gore & Associates, Inc.$1K
  • Boston Scientific$962
  • Abiomed$950
  • Abbott$727
  • Pfizer$348
  • plus $4K from 32 others

What the payments were for

  • Travel & lodging$1,63118%
  • Food & beverage$7,57382%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,203 in reported general payments places this provider in the 50th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$114,923
Medicare patients
709
Services billed
1,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban487$516,939
EntrestoSacubitril/Valsartan172$177,911
XareltoRivaroxaban111$107,310
JardianceEmpagliflozin102$85,847
Repatha SureclickEvolocumab71$57,235
FarxigaDapagliflozin Propanediol53$44,432
BrilintaTicagrelor41$37,546
Repatha SyringeEvolocumab11$9,840
Metoprolol Succinate533$7,606
Atorvastatin Calcium588$6,267
Diltiazem 24hr Er (Cd)Diltiazem Hcl143$5,000
Rosuvastatin Calcium314$4,404
Ranolazine ErRanolazine30$2,995
ClopidogrelClopidogrel Bisulfate362$2,782
Carvedilol285$2,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$348$516,939487 claims
NovartisEntresto$140$177,911172 claims
Johnson & JohnsonXarelto$114$107,310111 claims
Boehringer IngelheimJardiance$55$85,847102 claims
AstraZenecaFarxiga, Brilinta$200$81,97894 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Bethel Park

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →